Niagen Bioscience, Inc.

$13.04
(as of Jun 9, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Niagen Bioscience, Inc.

Stock Price
$13.04
Ticker Symbol
NAGE
Exchange
NASDAQ

Industry Information for Niagen Bioscience, Inc.

Sector
Healthcare
Industry
Biotechnology

Company Description for Niagen Bioscience, Inc.

Country
USA
Full Time Employees
104

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Fundamentals for Niagen Bioscience, Inc.

Market Capitalization
$836,534,144
EBITDA
$14,022,000
Dividends per Share
P/E Ratio
59
Forward P/E Ratio
65.36
Earnings per Share
$0.18
Earnings per Share Estimate Next Year
Profit Margin
13.07%
Shares Outstanding
78,769,696
Percent Owned by Insiders
34.44%
Percent Owned by Institutions
30.60%
52-Week High
52-Week Low

Technical Indicators for Niagen Bioscience, Inc.

50-Day Moving Average
200-Day Moving Average
RSI
77.57
0.59

Analyst Ratings for Niagen Bioscience, Inc.

Strong Buy
2
Buy
2
Hold
0
Sell
0
Strong Sell
0

News About Niagen Bioscience, Inc.

Jun 2, 2025, 7:35 AM EST
Over the last 7 days, the United States market has risen 1.7% and over the past year, it has climbed 12%, with earnings forecast to grow by 14% annually. See more.
May 20, 2025, 1:45 PM EST
As the U.S. stock market experiences a slight downturn following a series of gains, investors are keenly observing opportunities that may arise from recent fluctuations in major indices like the S&P 500 and Nasdaq Composite. See more.
May 15, 2025, 7:39 AM EST
The United States market has shown robust performance with a 5.1% increase over the last week and an 11% rise over the past year, buoyed by forecasts of annual earnings growth at 14%. See more.